Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2020

01-12-2020 | NSCLC | ASO Author Reflections

ASO Author Reflections: Which of Smoking Duration or Smoking Intensity Contributes to Poor Prognosis After Resection of Non-small Cell Lung Cancer?

Authors: Shinkichi Takamori, MD, PhD, Tatsuro Okamoto, MD, PhD, Masaki Mori, MD, PhD

Published in: Annals of Surgical Oncology | Special Issue 3/2020

Login to get access

Excerpt

Cigarette smoking is an established cause of lung cancer. The pack-year index, which is calculated by multiplying the smoking period by the number of packs of cigarettes smoked per day, has been reported to be a significant prognostic indicator in non-small cell lung cancer (NSCLC) patients who receive curative lung resection.1 However, few studies have focused on the clinical implications of smoking duration (years) and smoking intensity (number of packs smoked per day), especially with regard to prognostic factors in patients with resectable NSCLC. Therefore, in the current retrospective study, we analyzed which of smoking duration or smoking intensity contributes to poor prognosis in NSCLC patients who undergo curative lung resection. …
Literature
1.
Kawai H, Tada A, Kawahara M, et al. Smoking history before surgery and prognosis in patients with stage IA non-small-cell lung cancer—a multicenter study. Lung Cancer. 2005;49(1):63–70.CrossRef
2.
3.
Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–8.CrossRef
4.
Raphael J, Batra A, Boldt G, et al. Predictors of survival benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer. 2020;21(2):106–13.CrossRef
Metadata
Title
ASO Author Reflections: Which of Smoking Duration or Smoking Intensity Contributes to Poor Prognosis After Resection of Non-small Cell Lung Cancer?
Authors
Shinkichi Takamori, MD, PhD
Tatsuro Okamoto, MD, PhD
Masaki Mori, MD, PhD
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08852-5

Other articles of this Special Issue 3/2020

Annals of Surgical Oncology 3/2020 Go to the issue

ASO Author Reflections

ASO Author Reflections: Nodal Downstaging and Conversion to Breast-Conserving Surgery Following Neoadjuvant Endocrine Therapy

ASO Author Reflections

ASO Author Reflections: Extraskeletal Myxoid Chondrosarcoma: A Rare Sarcoma Associated With Prolonged Survival

ASO Author Reflections

ASO Author Reflections: The Oncologic Efficacy and Feasibility of Nephron-Sparing Surgery for Adult Xp11.2 Translocation Renal Cell Carcinoma

Correction

Correction to: Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence

ASO Author Reflections

ASO Author Reflections: Completion Thyroidectomy and Adherence to the 2015 American Thyroid Association Guidelines

ASO Author Reflections

ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas